BCR-ABL influences cell cycle [71] and DNA damage responses [72] to increase the incidence of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.